BFRG Overview

Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.

Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.

Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.

Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

New Whitepaper Release: BullFrog AI Holdings has published a whitepaper titled "AI in Bioinformatics," highlighting their technology's ability to transform complex data into actionable insights for drug development.

Addressing Bioinformatics Challenges: The whitepaper identifies key pitfalls in bioinformatics that contribute to high clinical trial failure rates and presents BullFrog AI's bfLEAP platform as a solution through causal inference modeling.

Industry Transformation Potential: BullFrog AI aims to bridge the gap between data availability and actionable biological understanding, positioning its modular approach as essential for AI-enabled R&D in pharmaceuticals and biotech.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and potential, emphasizing the uncertainties and risks involved in their projections.

Stock Offering: Bullfrog AI (NASDAQ: BFRG) has filed to sell 5 million shares of common stock for existing holders.

Preliminary Prospectus: The filing is a preliminary prospectus and does not constitute an offer to sell the shares.